Abstract: The invention provides Helicobacter polypeptides that can be used in vaccination methods for preventing or treating Helicobacter infection, and polynucleotides that encode these polypeptides.
Type:
Application
Filed:
November 16, 2001
Publication date:
July 3, 2003
Inventors:
Rainer Haas, Harold Kleanthous, Jean-Francois Tomb, Charles Miller, Amal Al-Garawi, Stefan Odenbreit, Thomas Meyer
Abstract: The invention refers to the use of a lacrophyl preparation containing lysozyme, tris(hydroxymethyl)aminomethane, if desired other lacrophyl components, preferably ascorbic acid and/or citric acid and/or ethylenediamine-tetraacetic acid, in the rest distilled water for the dissolution of an active substance being insoluble or only slightly soluble in water or physiological saline, for preparing eye-drops, and/or in case of eye-drops containing an active substance to adjust optionally an active substance medium appropriate to the composition of the native tear and for the microbiological protection of the medium.
Abstract: The present invention relates to a composition for topical use for treating and improving the aesthetic conditions of the skin, which comprises, as an active ingredient, a mixture of ethyllinoleate and triethylcitrate. This composition is active in the treatment of seborrhea and acne.
Abstract: A method for treating a patient having meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion, is disclosed. Preferably, the method concerns treatment of a patient with topical tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline (CMT). Oral administration of a CMT is also disclosed as part of the method for treating meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion.
Type:
Application
Filed:
August 22, 2002
Publication date:
June 19, 2003
Inventors:
Stephen C. Pflugfelder, Balakrishna L. Lokeshwar, Marie Selzer
Abstract: The present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.
Type:
Grant
Filed:
May 6, 1998
Date of Patent:
June 17, 2003
Assignee:
Vanderbilt University
Inventors:
William M. Mitchell, Charles W. Stratton
Abstract: A composition for targeted vesicular for treatment of H-Pylori infections and for protection of the cell. The composition contains lectins, phospholipids, sterols, and one or more drugs. The composition is useful for treating H-Pylori infections and other diseases associated therewith and also helps in protecting cell walls.
Abstract: Nitrate salts of antimicrobial agents for the preparation of antimicrobial medicaments, specifically antiviral, antifungal and antibacterial medicaments.
Abstract: The present invention is a wildlife nutritional supplement for free ranging ruminants including about 7.5-8.5% calcium, about 3.5% phosphorus, about 32-37% salt, at least one “B” series vitamin is selected from a group consisting of pantothenic acid, folic acid, riboflavin, niacin, thiamine, cobalamin, and pyridoxine hydrocholoride, about 16-19% sodium, about 0.15% magnesium, about 0.15% potassium, about 2.5% sulfur, about 1,200 PPM iron, about 20 PPM copper, about 105 PPM manganese, about 45 PPM zinc, about 5 PPM cobalt, about 1 PPM selenium, about 1 PPM iodine, about 50,000 IU/LB Vitamin A, about 20,000 IU/LB Vitamin D, about 50 IU/LB Vitamin E, about 134 MG/LB biotin, about 60 MG/LB ascorbic acid, oxytetracycline and fenbendazole.
Abstract: An object of the present invention is to provide a stable pharmaceutical composition for topical administration comprising minocycline as an active ingredient. According to the present invention, there is provided a pharmaceutical composition for topical administration comprising minocycline or a physiologically acceptable salt thereof in an oleaginous base.
Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections.
Abstract: A composition for pharmaceutical products and cosmetic products contains IgY egg yolk antibodies of SPF hens and microalgae extracts from Spirulina species, Spirulina varieties, and Chlorella species. The composition can also contain oxytetracycline and preservatives or antioxidants. The composition prepared as a salve is used for healing infected wounds and for preventing the infection of wounds.
Abstract: Methods for the treatment or prevention of disorders, including acute inflammatory disorders involving pathological responses of the immune system, such as viral hemorrhagic diseases, sepsis, rheumatoid arthritis and other autoimmune disorders, acute cardiovascular events, flare-ups and acute phases of multiple sclerosis, wasting disorders and other disorders involving deleterious expression of cytokines and other factors, are provided.
Abstract: As discussed above the present invention in a first aspect thereof relates to the use of a tetracycline, preferably minocycline, for manufacture of a pharmaceutical composition for treatment or prevention of a disorder selected from Parkinson's disease and related disorders, preferably Parkinson's disease.
Abstract: A method of treating (a) cold sores in and out of the mouth, (b) canker sores, (c) cancer wounds including but not limited to wounds such as those which fail to heal due to chemotherapy and radiation therapy, (d) surgical wounds of all types, (e) diabetes wounds, (f) decubitus ulcers, (g) athletes foot including chronic athletes foot and (h) scarring with doxycycline and/or cefaclor is disclosed.
Abstract: Provided is a topical pharmaceutical composition for the treatment of inflammatory dermatoses, including acne vulgaris, together with methods for its use. The composition and methods involve the topical use of an active agent effective in the treatment of inflammatory dermatoses plus a permeation-enhancing base that, in one embodiment, gives the composition a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5.
Type:
Application
Filed:
June 21, 2002
Publication date:
April 24, 2003
Inventors:
Howard I. Maibach, Eric C. Luo, Tsung-Min Hsu
Abstract: Compositions having synergistic effective amounts of one or more antibacterial agents, a nitroimidazole, and an antifungal agent effective against a Candida species. The compositions are particularly useful in the treatment of genitourinary infections.
Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
Type:
Application
Filed:
June 29, 2001
Publication date:
March 20, 2003
Inventors:
Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Beena Bhatia, David Messersmith, Laura McIntyre, Darrell Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul Verma, Tadeusz Warchol, Upul Bandarage
Abstract: The invention relates to a method for the antibiotic coating of bodies with interconnecting microcavities as well as bodies coated this way and their usage.
Type:
Application
Filed:
June 19, 2002
Publication date:
March 13, 2003
Applicant:
Heraeus Kulzer GmbH & Co. KG
Inventors:
Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kuhn
Abstract: Compounds, compositions and methods are provided for treating malaria parasites in vitro and in vivo by administering indolo[2,1-b]quinazoline-6,12-dione compounds of Formula I.
Type:
Grant
Filed:
May 8, 2001
Date of Patent:
March 11, 2003
Assignee:
The United States of America as represented by the Secretary
of the Army
Inventors:
Kevin K. Pitzer, John P. Scovill, Dennis E. Kyle, Lucia Gerena
Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
Abstract: The present invention relates to novel method of reducing microbial infections, especially bacterial infections, of animals, especially of aquatic animals such as fish maintained in tanks or aquaria. The present invention provides bathing and dipping methods for reducing a microbial infection of an animal with an antibiotic solution of enhanced antimicrobial activity comprising at least one chelating agent and at least one antibiotic effective against the microbial infection. The present invention also provides a method for reducing a microbial infection of an animal comprising bathing or dipping an animal having a microbial infection in an antimicrobial solution comprising the chelating agent EDTA, and at least one antibiotic, and optionally a pH buffering agent. The immersion of the aquatic animal in the antimicrobial solution containing the EDTA, antibiotic and pH buffering agent may be repeated until the microbial burden of the animal is eliminated.
Type:
Grant
Filed:
September 18, 2001
Date of Patent:
February 11, 2003
Assignee:
University of Georgia Research Foundation, Inc.
Inventors:
Richard E. Wooley, Branson W. Ritchie, Victoria V. Burnley
Abstract: The present invention relates to a method for increasing survival rate of cells in animal cell culture under hypoxia condition by adding antibiotics to the culture media. The method of present invention comprises a step of culturing animal cells in culture media containing antibacterial agent of quinolones, quinones, aminoglycosides or chloramphenicol at the concentration range of 0.1 to 1000 &mgr;g/ml. The invented method can be practically applied for high-density animal cell culture to produce recombinant proteins or cultured cells.
Type:
Application
Filed:
July 12, 2002
Publication date:
January 30, 2003
Inventors:
Jongwon Lee, Kyu-Won Kim, Mee-Jung Han, Moo Hwan Cho, Yang-Il Kim
Abstract: Provided herein is a new and useful method for modulating, and particularly inhibiting angiogenesis in an animal. Since numerous diseases and disorders are dependent upon angiogenesis for continued growth in an animal, modulating and particularly inhibiting angiogenesis permits ultimately ameliorating a variety of diseases and disorders. Also provided are novel assays for screening compounds which may have applications in modulating and particularly inhibiting angiogenesis.
Abstract: Methods of regulating gene expression in subjects using tetracycline-responsive fusion proteins are disclosed. In one embodiment, the method involves introducing into a cell the subject a nucleic acid molecule encoding a fusion protein which inhibits transcription, the fusion protein comprising a first polypeptide which binds to a tet operator sequence, operatively linked to a heterologous second polypeptide which inhibits transcription in eukaryotic cells; and modulating the concentration of a tetracycline, or analogue thereof, in the subject. The first polypeptide can binds to a tet operator sequence in the absence, but not the presence, of tetracycline. Alternatively, the first polypeptide can binds to a tet operator sequence in the presence, but not the absence, of tetracycline.
Type:
Application
Filed:
August 3, 2001
Publication date:
January 30, 2003
Applicant:
BASF Aktiengesellschaft and Knoll Aktiengesellschaft
Abstract: The present invention relates to a method for inhibiting apoptosis under ischemic condition, which comprises a step of administering antibiotics of quinolones, quinones, aminoglycosides or chloramphenicol to an individual under ischemic condition which lacks an adequate supply of oxygen and glucose. In accordance with the present invention, the antibiotics increase cell viability under hypoxic and hypoglycemic condition, assuring that they can be applied as a therapeutic agent for ischemia-associated diseases such as myocardial infarction and cerebral infarction.
Type:
Application
Filed:
July 12, 2002
Publication date:
January 30, 2003
Inventors:
Jongwon Lee, Kyu-Won Kim, Jong-Kyun Lee, Sang Jong Lee
Abstract: The present invention relates to a therapeutic agent for ischemia which inhibits apoptosis under ischemic condition. The therapeutic agent of present invention comprises antibacterial agents of quinolones, quinones, aminoglycosides or chlorampheni-col as an active ingredient. Since the invented therapeutic agent improved the viability of cells under hypoxic and hypoglycemic condition, it can be clinically for ischemic diseases such as applied as a potentiad drug for ischemia-associated infarction and cerebral infarction.
Type:
Application
Filed:
July 12, 2002
Publication date:
January 16, 2003
Inventors:
Jongwon Lee, Kyu-Won Kim, Jong-Kyun Lee, Sang Jong Lee
Abstract: The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted at the 7, 8, and/or 9 positions and methods for preparing the 4-dedimethylamino tetracycline compounds. Other tetracycline compounds are the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N—NH-Alkyl group at the C4 position. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified 4-dedimethylamino tetracycline compounds.
Abstract: This invention provides a method of inhibiting, preventing, and/or treating conjunctival filtering bleb leaks that may occur following glaucoma filtering surgery by administering Matrix Metalloproteinase inhibitors to glaucoma patients who have undergone such surgery. The invention additionally includes a method of using Matrix Metalloproteinase inhibitors to inhibit, prevent, and/or treat ischemic damage to the retina and optic nerve in patients in need of such treatment.
Type:
Grant
Filed:
April 25, 2001
Date of Patent:
January 7, 2003
Assignee:
New England Medical Center Hospitals Inc.
Inventors:
Joel S. Schuman, M. Elizabeth Fini, Shravan K. Chintala
Abstract: Medical devices, compositions and methods for treating or preventing atherosclerotic plaque rupture are disclosed. Specifically, medical devices that deliver to a treatment site metalloproteinase inhibitors (MMPI) are disclosed. The medical devices include catheters, guide wires, vascular stents, micro-particles, electronic leads, probes, sensors, drug depots, transdermal patches, and vascular patches. Representative MMPIs included zinc chelators, urea derivatives, caprolactone-based inhibitors, phoshoinamides, piperazines, sulfonamides, tertiary amines, carbamate derivatives, mercaptoalcohols, mecaptoketones, antimicrobial tertracyclines, non-antimicrobial tetracyclines, and derivatives and combinations thereof. In one embodiment a self-expanding vascular stent is coated with at least one MMPI and deployed at a site within an artery where vulnerable plaque has been identified.
Abstract: 13-substituted methacycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 13-substituted methacycline compounds are described.
Type:
Grant
Filed:
June 29, 2001
Date of Patent:
December 31, 2002
Assignees:
Paratek Pharmaceuticals, Inc., Trustees of Tufts College
Inventors:
Mark L. Nelson, Beena Bhatia, Laura McIntyre, Glen Rennie
Abstract: The present invention relates to methods of treating psoriasis by inhibiting one or more matrix metalloproteinase enzymes (“MMPs”). It is based, at least in part, on the discovery that the expression patterns of certain MMPs and related molecules are altered in patients suffering from psoriasis, relative to normal subjects. Certain expression patterns are altered even in unaffected skin of psoriasis-afflicted patients, although aberrancies are more pronounced in psoriatic lesions. In various non-limiting embodiments, the present invention provides for methods of treating psoriasis, including preventing the development of new psoriatic lesions, comprising administering, to subjects in need of such treatment, effective concentrations of compounds which inhibit the enzymatic activity of one or more MMP. Suitable inhibitors include tetracycline and its derivatives and various hydroxymate, carboxylic acid, and phosphonic acid derivatives.
Abstract: The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after said device has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising:
(A) at least one taurinamide derivative, and
(B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof, whereby there are no systemic anti-clotting and no systemic biocidal effects.
Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
Type:
Application
Filed:
June 29, 2001
Publication date:
December 19, 2002
Inventors:
Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy, Karen Stapleton, Tad Warchol, Paul Sheahan
Abstract: A method for producing antibiotic composites is described, which is characterized in that a salt, which can be subjected to plastic deformation and which consists of at least one cationic component of a protonated antibiotics base from the groups of aminoglycoside antibiotics, the lincosamide antibiotics and the tetracycline antibiotics and of at least one anionic components from the group of organic sulfates and/or organic sulfonates and/or fatty acid esters, is used as a binding agent for the fixation of inorganic composite components and/or possibly organic composite components and possibly for the molding of the composites while adding water, especially through pressing, extrusion, rolling, calendering and grinding processes.
Type:
Application
Filed:
March 19, 2002
Publication date:
December 19, 2002
Applicant:
Heraeus Kulzer GmbH & co.KG
Inventors:
Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kuhn
Abstract: Two separate compositions, one containing multiple doses of an anhydrous first composition that includes a first active ingredient that is hydrolytically unstable and which provides a benefit to the skin of a user; and a second aqueous composition which may or may not contain a second active ingredient. are packaged within and dispensed from a common dispenser. By packaging these two compositions in this manner, long shelflife, good aesthetics and convenient dispensing and application are provided.
Abstract: The present invention concerns an antibiotic/antibiotics preparation for resorbable and non-resorbable implants for human and veterinary medicine, for the treatment of local microbial infections in hard and soft tissue.
Type:
Application
Filed:
March 19, 2002
Publication date:
December 5, 2002
Applicant:
Heraues Kulzer GmbH & Co.KG
Inventors:
Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kuhn
Abstract: The present invention concerns the manufacture and use of an antibiotic/antibiotics preparation for human and veterinary medicine, for the treatment of local microbial infections in hard and soft tissue.
Type:
Application
Filed:
March 19, 2002
Publication date:
December 5, 2002
Applicant:
Heraues Kulzer GmbH & Co.KG
Inventors:
Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kuhn
Abstract: Pharmaceutical compositions for delivering an effective dose of an angiogenesis inhibitor consisting of a tetracycline or tetracycline such as minocycline. The effective dosage for inhibition of angiogenesis based on in vitro testing is between one and 500 micromolar. The compositions are delivered topically, locally or systemically using implants or injection. The composition is extremely selective for growth of endothelial cells, inhibiting growth, but is not cytotoxic at the effective dosages.
Type:
Grant
Filed:
April 13, 1994
Date of Patent:
November 19, 2002
Inventors:
Henry Brem, Rafael J. Tamargo, Robert A. Bok
Abstract: A method for producing an improved veterinary product is disclosed. The method comprises bringing a selected long-acting anticmicrobial formulation into intimate admixture with a predetermined amount of an anti-inflammatory agent and preparing the admixture for parenteral administration.
Abstract: A method of promoting the uptake of exogenous antimicrobial compounds by microbial cells is disclosed. In one embodiment, the method comprises the step of exposing the microbial cell to an amount of at least one sesquiterpenoid effective to enhance antimicrobial compound uptake in a microorganism and an antimicrobial compound. An antimicrobial composition comprising at least one sesquiterpenoid and an antimicrobial compound, the sesquiterpenoid being present in a concentration of between 0.1 mM and 50 mM, is also disclosed.
Type:
Application
Filed:
September 25, 2001
Publication date:
November 7, 2002
Inventors:
Eric A. Johnson, Byron F. Brehm-Stecher
Abstract: The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted with aryl, alkenyl, or alkynyl groups. The 7, 8, and/or 9 positions and methods for preparing such compounds. Other tetracycline compounds include the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N—NH-Alkyl group substituted at the C4 position as well as C2 Mannich derivatives. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified tetracycline compounds.
Abstract: According to the present invention there is provided a method for the treatment or prophylaxis of acidic gut syndrome resulting from the accumulation of acid and production of endotoxin in the gastrointestinal tract of a human or an animal, said accumulation resulting from the fermentation of carbohydrate in the gastrointestinal tract of said human or animal, wherein said method comprises administering to said human or animal an effective amount of an active agent capable of preventing or controlling acid and endotoxin accumulation in the gastrointestinal tract.
Abstract: The present invention relates to an antibiotic(s)-polymer combination, which under physiological conditions guarantees the continuous release of antibiotics over a period of several days and can be used in human and veterinary medicine. The invented antibiotic(s)-polymer combination is whereinin a homogeneous polymer mixture, consisting of one or more hydrophobic polymers from the groups of poly(methacrylic acid esters), the poly(acrylic acid esters) and the poly(methacrylic acid ester-co-acrylic acid esters) and one or more hydrophilic polymers from the group of polyethers, one or more slightly water-soluble antibiotics from the groups of aminoglycoside antibiotics, the lincosamide antibiotics, the tetracycline antibiotics and quinolone antibiotics, possibly an easily water-soluble antibiotic from the groups of aminoglycoside antibiotics, the lincosamide antibiotics and the tetracycline antibiotics, and possibly one or more organic adjuvants are suspended, and that this suspension forms a composite.
Type:
Application
Filed:
March 19, 2002
Publication date:
October 17, 2002
Applicant:
Heraues Kulzer GmbH & Co.KG
Inventors:
Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kuhn
Abstract: Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.
Abstract: Transgenic animals carrying two transgenes, the first coding for a transactivator fusion protein comprising a tet repressor and a polypeptide which directly or indirectly activates in eucaryotic cells, and the second comprising a gene operably linked to a minimal promotor operably linked to at least one tet operator sequence, are disclosed. Isolated DNA molecules (e.g., targeting vectors) for integrating a polynucleotide sequence encoding a transactivator of the invention at a predetermined location within a second target DNA molecule by homologous recombination are also disclosed. Transgenic animals having the DNA molecules of the invention integrated at a predetermined location in a chromosome by homologous recombination are also encompassed by the invention. Methods to regulate the expression of a tet operator linked-gene of interest by administering tetracycline or a tetracycline analogue to an animal of the invention are also disclosed.
Type:
Application
Filed:
June 25, 2001
Publication date:
October 17, 2002
Applicant:
BASF Aktiengesellschaft
Inventors:
Hermann Bujard, Manfred Gossen, Jochen G. Salfeld, Jeffrey W. Voss
Abstract: 13-substituted methacycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 13-substituted methacycline compounds are described.
Type:
Application
Filed:
June 29, 2001
Publication date:
October 10, 2002
Inventors:
Mark L. Nelson, Beena Bhatia, Laura McIntyre, Glen Rennie
Abstract: Two separate compositions, one containing an antibiotic and one containing benzoyl peroxide are packaged within and dispensed from a common dispenser. More particularly, a dual dispenser contains i) a first composition that is substantially anhydrous and includes a polar solvent, an antibiotic and a thickening agent selected from the group consisting of acrylic acid polymers and polyacrylamides; and ii) a second composition containing benzoyl peroxide or, alternatively, a retinoid. By packaging these two anti-acne active ingredients in this manner, long shelflife and convenient dispensing and application are provided.